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Abstract
Background: An estimated between 257 and 292 million people live with chronic HBV globally. While much is
known about the causes, and epidemiology of HBV, little is understood about the quality of life and impact of HBV
on those living with the infection.
Methods: A random sample of HBV-related email queries sent to the Hepatitis B Foundation, a U.S.-based non-
profit organization, over a 12-month period in 2018–2019 were retrieved, tabulated, and analyzed qualitatively to
highlight information needs and explore the experiences of people living with HBV and their families and loved
ones. Codebook development was informed by the literature and through line-by-line reading of a sub-sample of
queries. Data analysis was facilitated by NVivo12 software. Data were coded independently by two members of the
research team and intercoder reliability was assessed to assure coding accuracy throughout the coding phase.
Results: A total of 338 queries from people around the globe were identified and analyzed. The analysis revealed
three thematic groups: 1) health-specific challenges associated with diagnosis and treatment, 2) emotional needs
related to experiences with HBV stigma, discrimination, fear, social isolation, and distress and 3) informational needs
related to HBV prevention and transmission, and interpretation of laboratory tests.
Conclusions: People living with HBV are in need of information to manage their disease and prevent its spread.
Analysis of queries uncovered significant misconceptions about HBV transmission and treatment. Additionally, the
emotional and psychological impact of an HBV diagnosis on those living with the infection is significant. There is a
clear need for patient and community education to expand knowledge and awareness of HBV globally to achieve
2030 WHO HBV elimination goals.
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Introduction
In 2018, it was estimated that between 257 and 292 mil-
lion people were living with chronic hepatitis B virus
(HBV) globally [1, 2]. In 2015, the World Health
Organization (WHO) estimated that 887,000 deaths
worldwide were attributed to HBV, mostly from cirrho-
sis and hepatocellular carcinoma (HCC) [1, 3]. Addition-
ally, there are antiviral therapies that effectively manage
HBV and decrease the risk of liver failure, liver cancer
and even death for those who are chronically infected
that meet treatment eligibility criteria [4]. Still, only an
estimated 10% (29 million) of those chronically infected
with HBV are diagnosed, and only 5% of those eligible
for treatment actually receive it [1].
While we have significant data on the global epidemio-
logical characteristics of HBV, the perspectives from
those living with HBV are often underrepresented within
literature [5]. As research moves towards finding a cura-
tive therapy for HBV and new therapeutics move into
clinical trials, those living with HBV should have the op-
portunity to assist and guide the development of new
treatments and resources based on their needs and per-
sonal experiences. It is essential that innovations and im-
provements in health infrastructure surrounding HBV
care are informed by common concerns and needs of in-
dividuals living with HBV. This qualitative study evalu-
ates patient and family member queries received by the
Hepatitis B Foundation to assess the most critical needs
and concerns of those affected by HBV.
Methods
Data collection
A random sample of HBV-related email queries sent to
the Hepatitis B Foundation (HBF), a U.S.-based non-
profit, over a 12-month period in 2018–2019 were retro-
spectively analyzed to highlight information gaps and
the lived experiences of those living with HBV. HBF re-
ceives emails (queries) as part of a helpline service run
by trained community health education specialists
(CHES) to provide information, resources and support
to people impacted by HBV. The CHES provide general
guidance for those living with HBV, basic HBV disease
specific information, and referrals to health care
providers.
In 2018 and 2019, the HBF received a total of 3849
and 4120 individual queries respectively from around
the world. A sample of 30 queries per month over the
12-month period were selected through systematic ran-
dom sampling (every 6th query pulled for analysis) by
study staff (CF) creating a sample of 338 queries for ana-
lysis (3 duplicate queries were removed, and 8 additional
queries were deemed irrelevant as they did not address
HBV) (Fig. 1). The sample size and sampling strategy
were developed to assure thematic saturation would be
achieved.
Analysis
A codebook was created to guide the organization of
data, and codes were developed by review of the litera-
ture (a priori) and through line-by-line reading of a
Fig. 1 The sampling strategy for queries received to the Hepatitis B Foundation between 2018 and 2019
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subsample of queries (Additional file 1) [6]. Each code
was given a specific definition to ensure coding accuracy
and to improve intercoder reliability [7]. Data coding
and analysis was facilitated using NVivo 12 software
(QRS International, Doncaster, Australia). All data were
independently double coded by two members of the re-
search team (SF, PK) to ensure coding accuracy. Inter-
coder reliability (ICR) was assessed, repeatedly using the
kappa coefficient, to identify coding discrepancies. The
analysis team met (PK, SF, CF, RF) throughout the cod-
ing process to discuss and resolve discrepancies in cod-
ing. After coding was complete, the team reviewed the
coding and organized findings into thematic categories.
This study was approved by the Heartland Institutional
Review Board and acknowledged by the Thomas Jeffer-
son University Institutional Review Board (IRB). No
identifiable information was included during query ex-
traction and the IRB provided a waiver of consent for
analysis as the research presents no more than minimal
risk to participants. This study was performed in accord-
ance with the ethical standards as laid down in the 1964
Declaration of Helsinki and its later amendments or
comparable ethical standards.
Results
The sampling strategy yielded 338 unique queries for
analysis (Fig. 1). Final ICR assessment yielded a mean
kappa score of .87 across all codes, which is evidence of
near perfect coding agreement [8]. Of these 338 queries,
102 participants identified their location: 32 countries
were identified (Fig. 2). A total of 316 participants iden-
tified the party for which they were seeking information:
250 (79%) were seeking information for themselves, and
54 (17%) for a close contact (family member, friend,
etc.). Analysis confirmed data saturation [7] was
achieved and revealed three thematic groups: 1) health-
specific challenges associated with HBV diagnosis, treat-
ment, 2) emotional impact related to experiences with
HBV stigma, discrimination, and fear, social isolation
and distress after diagnosis and 3) informational needs
related to prevention and transmission of HBV, and la-
boratory test interpretation. Each theme is described
below and, is supported by excerpts from the queries
and is visually represented in an explanatory model
(Fig. 3).
Health-specific challenges
Many people shared details about their physical pain as-
sociated with an HBV diagnosis. One individual shared,
“Am really incapacitated by this virus, I have been ex-
periencing pain on my right side above the abdomen for
almost a year now, am even unable to do any manual
work from where I earn a living.” Another noted, “I am
always tired and sick. My abdomen hurts every time I
Fig. 2 Geographic representation of the queries received between 2018 and 2019 by the Hepatitis B Foundation from those affected by
hepatitis B
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eat and accompany with chest and back pain. It’s the
worst feeling ever.”
Individuals also described challenges with cost and
treatment access; one person shared, “I’m only a jobless
high school graduates who barely afford daily meal. I’m
not financially empowered to afford necessary treatment
since they are expensive here.” Others described finan-
cial challenges with accessing medication long-term, “I
was diagnosed with hepatitis B at 2015 and I used to buy
some drugs to it but later I stopped it because I cannot
afford it.” Individuals asked to be connected to medica-
tion affordability resources in their countries. While
others expressed uncertainty about the availability of
treatment in their country.
Queries requested information on a cure for HBV
or asked how HBV could be eliminated or “destroyed,
” from their body. One individual shared, “Is there
any treatment which can cure the disease, please let
me know.” Others asked about the timing of the cure
and when it would be available. An individual shared,
“Pl [ease], if there [is a] permanent cure for chronic
HBV? Please my life depends on it! I want it off my
system and my joy will be complete.” The request for
a cure was one of the most commonly referenced
topics throughout the analysis.
Emotional impact
The emotional impact of those with an HBV diagnosis
came across as feelings of hopelessness and social isola-
tion. One individual shared, “I … believe that you will
link me to a group … to feel [I] am not alone in this
struggle, and also to [at last] have someone to marry …
you know [it] is very difficult … to disclose your infec-
tion to others who are not infected.” One individual de-
scribed, “I think I might die very soon because I am
already dying slowly no one to talk or where to seek
help.” Others echoed this sentiment, “I sometimes feel
my system is shutting down. I am worried that my days
may be numbered. Especially that hep B is termed silent
killer and its deaths occur suddenly.” One individual
expressed, “I am not a crazy party person and I live with
a single sex partner. I don’t know how this came to me...
I am so much shameful to discuss about Hepatitis B. So
much depressed with the results.”
Stigma and discrimination associated with an HBV
diagnosis led to significant barriers accessing employ-
ment opportunities. Many people described concerns
Fig. 3 Ecological model demonstrating the interconnection between overarching themes 1) informational needs associated with prevention and
transmission of HBV and laboratory and test interpretation; 2) health-specific challenges associated with diagnosis and treatment and 3) emotional
impact related to experiences with HBV stigma, discrimination, and the fear, social isolation and distress after diagnosis from a sample of queries
from individuals living with HBV
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related to sharing one’s HBV status with others as well
as the need for emotional support and connection to
others with HBV. One individual described, “I am look-
ing for online supports for her … She has a lot of con-
cern about the stigma of the illness and worry that
others will reject her if she discloses her status.” Another
individual described that the stigma was preventing
them from seeking medical care by sharing, “I have nei-
ther done further tests nor taken any medication. This is
partly because of the cost of some of recommended tests
and the stigma associated with it.”
Individuals also experienced loss of employment both
within their country and when attempting to work
abroad due their HBV diagnosis. One individual reached
out for help, sharing, “I was diagnosed with Hep B and I
was stopped from going abroad to work. Medication for
hepatitis B is not common in Uganda.” A few individuals
shared that their permits were denied due to their HBV
status, “… unfortunately I was hepatitis b positive and I
was told my residence permit is denied.” Another indi-
vidual shared fear of going to the hospital because of a
diagnosis with HBV, “I read in the student handbook
given to me that foreigner can be detained if discovered
to have dangerous communicable diseases. I’m therefore
scared of visiting any of the hospitals in (name removed)
for checkup.” This discrimination was even described in
the United States Military, “I am Sargent First Class in
the United States Army … I found out I had chronic
Hepatitis B … Due to recent changes on the rules and
regulations that [cover] my illness … the possibility that
I will have to be medically separated with no
compensation.”
Informational needs
Findings suggest that those living with HBV have a de-
sire and need for more information related to HBV pre-
vention and diagnosis. Many asked if regular booster
doses of the vaccine were required to maintain immun-
ity. Other queries reported confusion regarding the
long-term effectiveness of the vaccination. One partici-
pant asked, “If an individual has received hepatitis B vac-
cine as a baby, at what age should he or she revaccinate
against hepatitis virus?” A common question focused on
whether those with a current infection can get vacci-
nated to get rid of the virus. One person asked, “[Can I]
get vaccinated after I exposed the virus, what are the
consequences of getting vaccinated after 6 months when
the virus still in the body.” One physician asked, “I am a
doctor, I started hepatitis B vaccine on 1-11-2018, I de-
layed the 2nd shot and I took it on 5-12-2018. Do I have
to repeat doses from the start?” Another individual
asked, “If that is vaccinated with three shots of vaccine
at interval of 0,1,6 months can they have sex without
using condom? Does it infect her wife? If they cannot
have sex without condom then how can they have their
own child?”
Individuals requested information on how to prevent
transmission to their families and close contacts. A
father concerned about transmission to his son de-
scribed, “I have hugged him since my son was born. I
have been walking with him now. Sometimes I have a
cold and runny nose, but I am just holding him, no kis-
sing him at all. Will this [give] hepatitis B … to my
child?” Several family members asked about concerns re-
garding familial transmission, one individual described,
“My father is hepatitis B positive. May I share clothes or
towel with him?” Another individual, similarly, had a
question about being in a relationship and having chil-
dren with someone who is living with HBV. This indi-
vidual shared, “If I have been vaccinated against
hepatitis, can I be able to marry a girl with hepatitis
virus and give birth to safe baby that are (HBV) nega-
tive?” Another asked, “I am about to marry a hepatitis B
(infected) man, we’ve never had sex or even kiss. Please
is it possible that I and my kids will never have hepatitis
B after vaccination?”
Many individuals sent lab test results directly for inter-
pretation and recommendations. An individual stated, “I
done my HBsAg. Test last day and I have the result with
value of 2565 is that mean that I am infected with HBs
positive? If yes is that acute or chronic? And is that cur-
able?” Another person shared results and concern for life
longevity after receiving test results, stating, “How long
we can live [I am] affected by the virus and 50ul/mg is
my viral load is its cause serious.” Others shared they
had just been told by a doctor their HBV status with
limited explanation, “I was doing medicals, and one of
my results was Hep B reactive but the doctor didn’t tell
me anything about it. am I okay?” There were also con-
cerns regarding pregnancy and test results. One preg-
nant woman said, “I’m pregnant now 7 months and
during antenatal checkup I was tested HBsAg- reactive,
HBsAb - nonreactive, HBeAg - nonreactive, HbeAb- re-
active, HbcAb - reactive. Please explain to me the re-
sult.” Laboratory interpretation made up a significant
proportion of total queries.
Limitations
Although this research was able to capture the unique
needs of people directly impacted by HBV, the study
sample may not be representative of the larger HBV-
affected population. The sample itself is also biased as
those reaching out to HBF are often coming to the help-
line with questions. The study results could also poten-
tially be skewed due to geographic bias. This study’s
sampling methods may have also contributed to having
a less representative sample, limiting study
generalizability. The sole use of email-based
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correspondence could affect sample representativeness
because this method limits the sample to individuals
who have access to working internet, English language
proficiency, and email accounts. While there are biases
within the sample, the most commonly asked questions
for individuals living with HBV determine gaps in know-
ledge and demonstrate the demand for the equitable dis-
tribution of accurate information about the infection
particularly shortly after diagnosis.
Discussion
Qualitative analysis revealed three overarching themes 1)
informational needs associated with prevention and
transmission of HBV and laboratory and test interpret-
ation; 2) health-specific challenges associated with diag-
nosis and treatment and 3) emotional impact related to
experiences with HBV stigma, discrimination, and the
fear, social isolation and distress after diagnosis from a
sample of queries from individuals living with HBV. It is
important to emphasize the overlap in relationships of
specific themes found within the data (Fig. 3). For ex-
ample, when individuals asked for laboratory interpret-
ation, they often asked questions related to life
expectancy after diagnosis, defended their lifestyle in an
effort to de-stigmatize their diagnosis, or requested cura-
tive therapy or treatment for their diagnosis. An example
of this overlap, “I really need your help because I learned
I am hepatitis B virus carrier, and I don’t know what to
do … I think I might die very soon because I am already
dying slowing now one to talk or where to seek help. I
really want to get more information and get sensitized
about hepatitis B virus and how I can manage it properly
or get total cure.” Within this quote there is an intersec-
tion between a recent diagnosis of HBV, the desire for
more information and support, fear for the future, and
treatment needs. The initial reaction from an HBV diag-
nosis has been shown in previous literature to involve
significant stress and anxiety about the future and high-
light worry and concern related to premature death
[9–14].
Health-related quality of life is a multi-dimensional
concept related to physical, mental, emotional, and so-
cial functioning [15]. Our analysis supports the claim
that HBV impacts health-related quality of life and often
negatively affects emotional health. For those with HBV,
without symptoms, the possibility of progression to liver
cancer and the lifelong nature of infection lead to the
perception of having severe disease regardless of disease
state [16, 17]. Previous studies have linked the infectious
nature of HBV, inadequate knowledge about transmis-
sion modes, and anxiety about transmissibility of the
virus to social isolation for those infected [17]. This iso-
lation as well as stigma, and discrimination might be
reasons for the evident psychological burden associated
with HBV [17]. Our study describes the most commonly
asked questions for individuals living with HBV deter-
mine gaps in knowledge and demonstrate the demand
for the equitable distribution of accurate information
about the infection particularly shortly after diagnosis.
Additionally, we demonstrate the need for resources de-
voted to addressing HBV indicators of health-related
quality of life and its psychological burden in vulnerable
communities worldwide.
A common concern for individuals was the fear of
transmission and desire to prevent HBV from infecting
their loved ones, which has similarly been reported
within the literature [5]. The common misconception
that HBV can be spread casually (through hugging, kis-
sing, sharing food) emerged from queries and is consist-
ent with other findings assessing general knowledge
associated with HBV our research supports this [18, 19].
Additionally, like others, our findings also suggest that
people living with HBV frequently report worry and fear
of passing the virus to their close contacts and family
members, as we have demonstrated within this analysis
[5, 9, 10, 14, 20, 21]. This fear leads to self-
stigmatization and self-isolation, which is seen both in
the emotional and physical impact of living with HBV
[5]. Literature demonstrates those with HBV have sig-
nificant anxiety and depression which is further sup-
ported within the queries [17].
Feelings and experiences with HBV-related stigma
were extremely prevalent in this study. Many individuals
living with HBV commonly felt shame and embarrass-
ment related to their diagnosis. Previous research has
identified stigma and HBV as negatively associated with
help-seeking, screening, disclosure, prevention of trans-
mission, and adherence to treatment for HBV [5, 22].
Additionally, research shows that HBV-associated stigma
had potentially negative impacts on mental health, well-
being, employment, and relationships and is a major bar-
rier to addressing HBV [22, 23]. Queries from this study
provide evidence to support this as well as wide-spread
discrimination people with HBV experience when seek-
ing education, employment, and residency in various
countries which directly affects their careers, ability to
immigrate, and their subsequent quality of life. It will be
important moving forward to systematically define and
document HBV- related discrimination, as it relates to
employment, education, and immigration/residency, so
that it can be understood and addressed. Governments
should ensure that legal protections are in place to pro-
tect people living with HBV from discrimination.
Data revealed common misconceptions around HBV,
including myths that the HBV vaccine can cure someone
who is already infected, that people always need treat-
ment immediately after diagnosis, and that there is cur-
rently a cure for HBV. This discrepancy is likely due to
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poor or incomplete knowledge related to HBV, treat-
ment mechanisms, and prevention which is consistent
with the literature [10]. Queries revealed the desperation
and “hopelessness” of recently diagnosed individuals and
their desire for a cure to completely remove HBV from
their body.. Individuals also commonly held the belief
that HBV was a “death sentence” and the emotional toll
after diagnosis can create significant challenges mentally
and physically which has also been shown in literature
[5]. In large multi-national studies of patient reported
HBV outcomes, poorer health-related quality of life was
related to advanced liver disease. The common theme of
anxiety is described as advanced liver disease and phys-
ical symptoms manifest for those with HBV [21, 24, 25].
Having access to appropriate medical care and treatment
could help to alleviate some of the fear and anxiety as
well as access to accurate disease-related information to
address common misconceptions that exacerbate fear
and anxiety.
Data demonstrate that persons with HBV experience
substantial barriers related to accessibility and cost of
treatment as well as the burden of HBV management.
HBV management requires regular monitoring by a
knowledgeable provider, but for many low- to middle-
income countries, finding a doctor competent on HBV
management and being able to afford regular care and
medication is a significant challenge. In low income
countries a health disparity associated with HBV is re-
lated to access to and cost of treatment [5, 10, 23]. HBV
treatment has to be taken long-term, with the cost vary-
ing significantly across the world creating challenges in
lifelong management of the disease [4]. Additionally, as
new therapies currently in development move through
clinical trial, it is important that accessibility be consid-
ered a top priority particularly within low-income coun-
tries where HBV is endemic.
A concerning finding from these data was the wide-
spread confusion about interpretation of lab tests. Many
individuals indicated that their providers did not explain
their test results, did not answer all of their questions
due to time constraints, and did not demonstrate ad-
equate knowledge on HBV. This has also been seen in
previous research [26]. Future resources should focus on
expanding provider training around the globe, particu-
larly in low income countries [27]. Guidelines should
also be simplified so medical management of HBV is
easy to understand at the primary care level and applic-
able in countries with limited resources. Additionally,
psychological health improvement programs in medical
centers to improve a patient’s self-efficacy and confi-
dence can help individuals cope at the time of their diag-
nosis [13]. Provider consultation should also highlight
disease progression for those with HBV to address
misconceptions and expectations for management [28].
Conclusion
In 2015, the World Health Assembly passed the Global
Health Sector Strategy on Viral Hepatitis, which aims to
eliminate HBV by 2030 [29]. In order to achieve these
goals, it is essential that the perspectives and needs of
those living with HBV are considered particularly related
to health-related quality of life indicators. This study
demonstrates a significant need to address widespread
misconceptions about HBV that impact stigma and dis-
crimination, expand both individual and provider level
HBV education, and increase global access to vaccin-
ation, care, and treatment. As more treatments for HBV
move through clinical trials, it is critical to consider the
perspective and needs of those directly affected by the
disease and ensure they are appropriately informed
about their condition. Future efforts should expand the
general public knowledge on transmission to reduce
stigma, discrimination and the emotional burden associ-
ated with HBV. Future efforts should work to break
down stigma and promote disclosure around HBV status
so that individuals, if managed appropriately, can live a
normal life. Clinical guidelines should also be simplified
so management is readily available at the primary care
level and applicable in low- and middle-income coun-
tries with limited resources. Efforts and prioritization
should also be made to reduce barriers associated with
treatment access across the globe for HBV.
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